ZOM Key Statistics, Chart & Performance
The current stock price of ZOM is 0.0973 USD. In the past month the price decreased by -19.59%. In the past year, price decreased by -30.94%.
ZOM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.23 | 218.96B | ||
| ISRG | INTUITIVE SURGICAL INC | 68.09 | 207.82B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.1 | 144.75B | ||
| SYK | STRYKER CORP | 27.91 | 140.55B | ||
| BDX | BECTON DICKINSON AND CO | 14.06 | 57.87B | ||
| IDXX | IDEXX LABORATORIES INC | 56.57 | 56.96B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.12 | 49.40B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 19.02 | 39.76B | ||
| RMD | RESMED INC | 25.5 | 36.85B | ||
| DXCM | DEXCOM INC | 36.24 | 26.29B | ||
| PODD | INSULET CORP | 63.25 | 20.33B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.48 | 18.40B |
Related stock screener links
About ZOM
Company Profile
Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company is headquartered in Ann Arbor, Michigan and currently employs 144 full-time employees. The company went IPO on 2013-10-28. The firm is engaged in creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. The firm's product portfolio includes diagnostics and medical devices that emphasize patient health and practice health. Its Diagnostics segment consists of TRUFORMA, VetGuardian, and TRUVIEW products. Its Therapeutic Devices segment consists of Assisi and PulseVet products. Its TRUFORMA platform comprises point-of-care diagnostic products for disease states in dogs, cats and horses, providing assays for use at the point-of-care that provide reference lab accuracy. Its TRUVIEW platform consists of the TRUVIEW digital cystoscopy instrument providing microscopic images and related pathology services which enable practitioners to receive a pathologist interpretation of the images. The Assisi Loop platform includes a series of products that use targeted pulsed electromagnetic field (tPEMF) therapy.
Company Info
ZOMEDICA CORP
100 Phoenix Drive, Suite 125
Ann Arbor MICHIGAN 48108 US
CEO: Robert Cohen
Employees: 144
Phone: 17343692555
ZOMEDICA CORP / ZOM FAQ
Can you describe the business of ZOMEDICA CORP?
Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. The company is headquartered in Ann Arbor, Michigan and currently employs 144 full-time employees. The company went IPO on 2013-10-28. The firm is engaged in creating products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. The firm's product portfolio includes diagnostics and medical devices that emphasize patient health and practice health. Its Diagnostics segment consists of TRUFORMA, VetGuardian, and TRUVIEW products. Its Therapeutic Devices segment consists of Assisi and PulseVet products. Its TRUFORMA platform comprises point-of-care diagnostic products for disease states in dogs, cats and horses, providing assays for use at the point-of-care that provide reference lab accuracy. Its TRUVIEW platform consists of the TRUVIEW digital cystoscopy instrument providing microscopic images and related pathology services which enable practitioners to receive a pathologist interpretation of the images. The Assisi Loop platform includes a series of products that use targeted pulsed electromagnetic field (tPEMF) therapy.
Can you provide the latest stock price for ZOMEDICA CORP?
The current stock price of ZOM is 0.0973 USD. The price decreased by -0.21% in the last trading session.
Does ZOM stock pay dividends?
ZOM does not pay a dividend.
How is the ChartMill rating for ZOMEDICA CORP?
ZOM has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What do analysts say about ZOMEDICA CORP (ZOM) stock?
5 analysts have analysed ZOM and the average price target is 0.26 USD. This implies a price increase of 162.08% is expected in the next year compared to the current price of 0.0973.
How many employees does ZOMEDICA CORP have?
ZOMEDICA CORP (ZOM) currently has 144 employees.
ZOM Technical Analysis
ZOM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ZOM. No worries on liquidiy or solvency for ZOM as it has an excellent financial health rating, but there are worries on the profitability.
ZOM Financial Highlights
Over the last trailing twelve months ZOM reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS decreased by -57.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -29.05% | ||
| ROE | -30.66% | ||
| Debt/Equity | 0 |
ZOM Forecast & Estimates
5 analysts have analysed ZOM and the average price target is 0.26 USD. This implies a price increase of 162.08% is expected in the next year compared to the current price of 0.0973.
For the next year, analysts expect an EPS growth of -110.78% and a revenue growth 10.67% for ZOM